Zevra Therapeutics Beats FY25 Revenue by 6%, Posts $83M Net Income Turnaround
ZVRA sits 71% above its 52-week low of $6.19.
Summary
Zevra Therapeutics reported strong financial results for fiscal year 2025, with revenue reaching $106.47 million, surpassing analyst expectations of $100.38 million. The company also achieved a significant turnaround in profitability, posting a net income of $83.2 million for the year. This positive performance was primarily driven by robust sales of its rare disease therapy, MIPLYFFA, which secured 68% market access coverage in the U.S. The strong commercial execution and improved financial health are material positives for the company. Investors will now focus on Zevra's continued global expansion efforts for MIPLYFFA and further regulatory progress in the EU.
At the time of this announcement, ZVRA was trading at $10.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $513.4M. The 52-week trading range was $6.19 to $13.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.